Open AccessResponse to pegylated interferon in a COVID‐19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus
Author(s) -
Frankel Arthur E.,
Yip Wai C.,
Naik Eknath,
Hasselbalch Hans C.
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4218
Subject(s) - everolimus , medicine , clearance , interferon , covid-19 , pegylated interferon , virology , neuroendocrine tumors , alpha interferon , gastroenterology , virus , ribavirin , chronic hepatitis , urology , disease , infectious disease (medical specialty)
A 61‐year‐old male on everolimus had chronic SARS‐CoV‐2 infection. Addition of pegylated interferon cleared viral RNA and supports combination therapy with everolimus plus interferon for COVID‐19.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom